Summarised Press Kit Information

The following document is a summary of popular queries related to Neuromod Devices Ltd. For more information or a detailed press kit, email **Neuromod Head of Communications**, Joe Roche at joe.roche@neuromoddevices.com or call +353 (87) 4160138.

- **Company**: Neuromod Devices Ltd is a medical technology company specialising in the design and development of neuromodulation technologies to address the needs of underserved patient populations who live with chronic and debilitating conditions.
- **Neuromod Founding**: Neuromod was founded in 2010 by Dr. Ross O'Neill based on technology developed at Maynooth University, Dublin.
- **Neuromod USA Inc**: Neuromod USA Inc., incorporated in 2021, is a wholly owned subsidiary of Neuromod Devices Ltd. and is headquartered in Illinois. Neuromod USA Inc. has partnered with audiologists and hearing health specialists across the United States of America to boost access to Lenire and treatment delivery success.
- **Offices and Headcount**: Neuromod employs 60+ global employees spanning our offices in Ireland, Germany and the United States of America.
- **Lenire Tinnitus Treatment**: Neuromod developed Lenire, the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in three large-scale clinical trials.
- **How Lenire Works**: Watch this Lenire Mechanism Video to learn more.
- **European Availability**: Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe and is currently available in 35 European countries.
- **TENT-A3**: Neuromod worked in collaboration with the United States Food and Drug Administration (FDA) to design a clinical trial to further test the safety and efficacy of Lenire as a tinnitus treatment. Following the success of TENT-A3, Lenire was granted De Novo approval by the FDA for tinnitus treatment in the United States of America.
    - TENT-A3 was a controlled clinical trial designed in collaboration with the FDA.
    - Lenire is the only bimodal neuromodulation device that has been granted approval by the FDA for tinnitus treatment in the United States of America.
    - TENT-A3 trialled Lenire on 112 patients from March – October, 2022.
    - 88.6% of TENT-A3 participants would recommend Lenire to treat tinnitus.

    - 70.5% of patients with moderate and up tinnitus had a significant reduction in tinnitus after six weeks having had no response to audio-only therapy.
    - Results of TENT-A3 are consistent with real world data collected across 204 tinnitus patients from the tinnitus care clinic, Ótologie.
- **Aggregate Clinical Trials**: Lenire is proven as safe and effective tinnitus treatment technology across three large scale clinical trials involving more than 500 subjects.
    - 83% of 500+ clinical trial patients would recommend Lenire to treat tinnitus.
    - Lenire is backed by the world's leading tinnitus and neuroscience researchers from the Tinnitus Research Initiative, National Institute for Health Research Nottingham Biomedical Research Centre and the University of Texas.
    - Zero serious adverse side effects were detected across all three clinical trials proving Lenire to be effective and inherently safe.
- **Real World Patients**: You can watch real world patient stories here.